Karyopharm Therapeutics | KPTI - 流动资产



金融业
股票价格
USD
资产
USD 131.42M
现金及等价物
USD 90.85M
销售成本
USD 1.35M
流动资产
USD 126.33M
流动负债
USD 117.3M
债务
USD 299.23M
股息收益率
0
EBIT
USD -26.76M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -1.02
股本和储备
USD -265.65M
销售毛利
USD 33.72M
债务利息支出
USD 12.55M
利息收入
USD -0.15
贷款资金
USD 264.49M
市值
USD 198.5M
净收入
USD -22.39M
营业费用
USD 61.83M
营业利润
USD -26.76M
普通股股本
USD 22.54M
税前利润
USD -22.39M
销售收入
USD 35.07M
销售和管理费用
USD 10.42M
股票
USD 4.04M
贸易债权人
USD 4.28M
应收帐款人
USD 23.36M


流动资产 更改 日
AbbVie USD 33.67B 140M 2026-06
Abbott USD 25.51B 488M 2026-03
Amgen USD 34.96B 3.49B 2026-06
AstraZeneca USD 27.97B 1.65B 2026-06
BioCryst Pharmaceuticals USD 484.68M 111.06M 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Eli Lilly USD 64.67B 9.84B 2026-06
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
GlaxoSmithKline GBP 17.56B 202M 2026-06
Incyte USD 6.03B 542.31M 2026-06
J&J USD 59.77B 601M 2026-06
Karyopharm Therapeutics USD 126.33M 23.19M 2026-03
MacroGenics USD 321.69M 139.16M 2026-06
Merck USD 36.68B 1.66B 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Novartis USD 27.35B 744M 2026-06
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 41.36B 1.46B 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Takeda JPY 3.15T 59.77B 2026-06
Tectonic Therapeutic USD 239.89M 17.47M 2026-03
TG Therapeutics USD 1.15B 58.72M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Xencor USD 523.21M 40.36M 2026-06